Astrazeneca PLC

Mani Sharma, SVP, Group Controller of Astrazeneca Plc, received 2 shares of common stock on August 6, 2026.

Mani Sharma, SVP of AstraZeneca, acquired ordinary shares under the company's Share Incentive Plan.

Mani Sharma, SVP of AstraZeneca, acquired ordinary shares under the company's Share Incentive Plan.

AstraZeneca SVP and Group Controller Mani Sharma sold 11,893 ordinary shares of the company on May 20, 2026.

Mani Sharma, SVP and Group Controller at AstraZeneca, acquired additional shares through the company's Share Incentive Plan in April and May 2026.

AstraZeneca PLC, through its subsidiary MedImmune Limited, has reaffirmed its 8.3% beneficial ownership in Innate Pharma SA.

AstraZeneca and its subsidiary now hold a 44% stake in Cellectis after converting preferred shares, with the ability to resell these shares publicly.

Vanguard Capital Management reports beneficial ownership of over 77.9 million shares, representing 5.02% of AstraZeneca PLC's common stock.

AstraZeneca PLC and its subsidiary Alexion Pharmaceuticals, Inc. have disclosed a 7.8% beneficial ownership stake in Monopar Therapeutics Inc. as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in AstraZeneca PLC as of March 31, 2025.

AstraZeneca PLC and its subsidiary AstraZeneca AB have filed an amended Schedule 13G, reporting a 1.1% passive beneficial ownership stake in Conduit Pharmaceuticals Inc.